← Eichor
Study identifier: NCT05582499 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Condition: Breast Neoplasm · Breast Cancer · Breast Tumors  ·  Sponsor: Fudan University

PhasePhase 2
Planned participants716
Who can joinFemale, 18 Years to 70 Years
Healthy volunteersNo

About this study

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Zhimin Shao, Professor  ·  +86(021)64175590  ·  zhimingshao@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center Shanghai, China, 200032Shanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05582499